Increased Protein Synthesis [PE] - N0000009533

Pharmacologic Code	N0000009533
Pharmacologic Name	Increased Protein Synthesis
Pharmacologic Uses	antisense oligonucleotide survival motor neuron-2 (SMN2)-directed antisense oligonucleotide survival of motor neuron 2 (SMN2) splicing modifier
Pharmacologic Concept	Physiologic Effects - [PE]
Pharmacologic Concept Description	This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept.

The table contains 5 products whose active ingredient are classified under the same pharmacologic class Increased Protein Synthesis [PE].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	50242-175	Evrysdi	Non-Proprietary Name: Risdiplam	Powder, For Solution	Oral	Genentech, Inc.	ACTIVE
	50242-202	Evrysdi	Non-Proprietary Name: Risdiplam	Tablet	Oral	Genentech, Inc.	ACTIVE
	60923-227	Amondys 45	Non-Proprietary Name: Casimersen	Injection	Intravenous	Sarepta Therapeutics, Inc.	ACTIVE
	60923-465	Vyondys 53	Non-Proprietary Name: Golodirsen	Injection	Intravenous	Sarepta Therapeutics, Inc.	ACTIVE
	64406-058	Spinraza	Non-Proprietary Name: Nusinersen	Injection, Solution	Intrathecal	Biogen Inc.	ACTIVE